Clinical Trial: NCT05224141
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2025-07-08 |
Study Overview
Brief Summary
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.
Official Title
Conditions
Intervention / Treatment
- Biological: Pembrolizumab/Vibostolimab Co-Formulation
- Drug: Saline placebo
- Drug: Etoposide
- Drug: Cisplatin
- Biological: Atezolizumab
- Drug: Carboplatin
Other Study ID Numbers
- 7684A-008
- MK-7684A-008
- KEYVIBE-008
- jRCT2021220008
- 2023-503517-30-00
- U1111-1287-4436
- 2021-005034-42
- 2023
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2025-07-08 |
Study Overview
Brief Summary
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.
Official Title
Conditions
Intervention / Treatment
- Biological: Pembrolizumab/Vibostolimab Co-Formulation
- Drug: Saline placebo
- Drug: Etoposide
- Drug: Cisplatin
- Biological: Atezolizumab
- Drug: Carboplatin
Other Study ID Numbers
- 7684A-008
- MK-7684A-008
- KEYVIBE-008
- jRCT2021220008
- 2023-503517-30-00
- U1111-1287-4436
- 2021-005034-42
- 2023